tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2026-075tumors-1631Research ArticleОБЗОРЫ И АНАЛИТИКАREVIEWS AND ANALYSISВозможность применения тактики “watch and wait” в терапии пациентов с немелкоклеточным раком легкого (обзорная статья)The possibility of using “watch and wait” approach in the treatment of patients with non-small cell lung cancer (literature review)https://orcid.org/0009-0008-6581-6541СейнароеваЕ. Х.SeynaroevaE. H.

Ева Хасановна Сейнароева

119991 Москва, ул. Трубецкая, 8, стр. 2

Eva Hasanovna Seynaroeva

Build. 2, 8 Trubetskaya St., Moscow 119991

seynaroeva_e_kh@student.sechenov.ruФГАОУ ВО «Первый Московский государственный медицинский университет им. И. М. Сеченова» Минздрава России (Сеченовский Университет)РоссияI. M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)Russian Federation20262104202616198–107Copyright © Сейнароева Е.Х., 20262026Сейнароева Е.Х.Seynaroeva E.H.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/1631Цель

Цель: Анализ мировых научных публикаций, посвященных методу “watch and wait” и перспективе его применения в группе пациентов с местнораспространенной формой НМРЛ.

Материал и методы

Материал и методы: Произведен поиск литературы с использованием медицинских баз данных: PubMed, Web of Science, РИНЦ, Scopus. Включение публикаций осуществлялось исходя из следующих критериев: рандомизированные и когортные исследования, систематические обзоры и мета-анализы.

Выводы

Выводы: Тактика “watch and wait” является перспективной опцией в терапии пациентов с НМРЛ и требует более глубокого изучения. Необходимо проведение проспективных исследований для определения ключевых параме‑ тров (критерии отбора пациентов, режимы наблюдения). Кроме того, требуется разработка эффективных методов оценки патоморфологического ответа.

Aim

Aim: to analyze global scientific publications dedicated to the “watch and wait” strategy and the prospects for its application in a g roup of patients with locally advanced non-small cell lung cancer (NSCLC).

Material and Methods

Material and Methods: a literature search was conducted using medical databases: PubMed, Web of Science, RSCI (Russian Science Citation Index), and Scopus. Publications were selected based on the following criteria: randomized and cohort studies, systematic reviews, and meta-analyses.

Conclusion

Conclusion: the “watch and wait” strategy is a promising option in the therapy of patients with NSCLC and requires more in-depth study. The conduct of prospective studies is necessary to determine key parameters (patient selection criteria, follow-up regimens). Furthermore, the development of effective methods for assessing the degree of pathological response is required.

рак легкого“watch and wait”«наблюдение и ожидание»безоперационная стратегиянеоадъювантная терапияпатоморфологический ответlung cancer“watch and wait”wait-and-see strategynon-surgical strategyneoadjuvant therapypathological responseReferencesBray F., Laversanne M., Sung H., et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74(3):229–263. https://doi.org/10.3322/caac.21834Bray F., Laversanne M., Sung H., et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74(3):229–263. https://doi.org/10.3322/caac.21834Forde P.M., Spicer J., Lu S., et al. CheckMate 816 Investigators. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 2022;386(21):1973–1985. https://doi.org/10.1056/NEJMoa2202170Forde P.M., Spicer J., Lu S., et al. CheckMate 816 Investigators. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 2022;386(21):1973–1985. https://doi.org/10.1056/NEJMoa2202170Provencio M., Nadal E., Insa A., et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 2020;21(11):1413–1422. https://doi.org/10.1016/S1470-2045(20)30453-8Provencio M., Nadal E., Insa A., et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 2020;21(11):1413–1422. https://doi.org/10.1016/S1470-2045(20)30453-8Wakelee H., Liberman M., Kato T., et al. KEYNOTE-671 investigators. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med. 2023 Aug 10;389(6):491–503. https://doi.org/10.1056/NEJMoa2302983Wakelee H., Liberman M., Kato T., et al. KEYNOTE-671 investigators. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med. 2023 Aug 10;389(6):491–503. https://doi.org/10.1056/NEJMoa2302983Кононец П.В. Торакоскопическая пневмонэктомия при раке. Клин. и эксперимент. хир. Журн. им. акад. Б. В. Петровского 2017;2:6–12.Kononets P.V. Thoracoscopic pneumonectomy for lung cancer. Clin. Exsperiment. Surg. Petrovsky J. 2017;2:6–12 (In Russ.)Пикин О.В., Рябов А.Б., Трахтенберг А.Х., и др. Анализ послеоперационных осложнений по системе ТММ у больных немелкоклеточным раком легкого после пневмонэктомии за 5-летний период. Хирургия. Журнал им. Н.И. Пирогова 2016;1:23–27. https://doi.org/10.17116/hirurgia20161223-27.Pikin O.V., Ryabov A.B., Trakhtenberg A.Kh., et al. Analysis of postoperative interventions using the TMM system in patients with non-small cell lung cancer after pneumonectomy over a 5-year period. Pirogov Russian Journal of Surgery. 2016;(1):23–27 (In Russ.). https://doi.org/10.17116/hirurgia20161223-27Jones G.D., Caso R., Tan K.S., et al. Propensity-matched analysis demonstrates long-term risk of respiratory and cardiac mortality after pneumonectomy compared with lobectomy for lung cancer. Ann Surg 2022;275(4):793–799. https://doi.org/10.1097/SLA.0000000000004065Jones G.D., Caso R., Tan K.S., et al. Propensity-matched analysis demonstrates long-term risk of respiratory and cardiac mortality after pneumonectomy compared with lobectomy for lung cancer. Ann Surg 2022;275(4):793–799. https://doi.org/10.1097/SLA.0000000000004065Habr-Gama A., Perez R.O., Nadalin W., et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004;240(4):711–7; discussion 717–8. https://doi.org/10.1097/01.sla.0000141194.27992.32Habr-Gama A., Perez R.O., Nadalin W., et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004;240(4):711–7; discussion 717–8. https://doi.org/10.1097/01.sla.0000141194.27992.32Habr-Gama A., de Souza P.M., Ribeiro U.Jr., et al. Low rectal cancer: impact of radiation and chemotherapy on surgical treatment. Dis Colon Rectum 1998;41(9):1087–96. https://doi.org/10.1007/BF02239429Habr-Gama A., de Souza P.M., Ribeiro U.Jr., et al. Low rectal cancer: impact of radiation and chemotherapy on surgical treatment. Dis Colon Rectum 1998;41(9):1087–96. https://doi.org/10.1007/BF02239429Marinelli D., Nuccio A., Di Federico A., et al. Improved event-free survival after complete or major pathologic response in patients with resectable nsclc treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis. J Thorac Oncol 2025;20(3):285–295. https://doi.org/10.1016/j.jtho.2024.09.1443Marinelli D., Nuccio A., Di Federico A., et al. Improved event-free survival after complete or major pathologic response in patients with resectable nsclc treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis. J Thorac Oncol 2025;20(3):285–295. https://doi.org/10.1016/j.jtho.2024.09.1443Reijers I.L.M., Menzies A.M., Lopez-Yurda M., et al. Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo. Eur J Cancer 2025;214:115141. https://doi.org/10.1016/j.ejca.2024.115141Reijers I.L.M., Menzies A.M., Lopez-Yurda M., et al. Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo. Eur J Cancer 2025;214:115141. https://doi.org/10.1016/j.ejca.2024.115141Forde P.M., Spicer J., Lu S., et al. CheckMate 816 Investigators. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 2022;386(21):1973–1985. https://doi.org/10.1056/NEJMoa2202170Forde P.M., Spicer J., Lu S., et al. CheckMate 816 Investigators. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 2022;386(21):1973–1985. https://doi.org/10.1056/NEJMoa2202170Zhang Z., Lin Y., Chen S. Efficacy of neoadjuvant, adjuvant, and perioperative immunotherapy in non-small cell lung cancer across different PD-L1 expression levels: a systematic review and meta-analysis. Front Immunol 2025;16:1569864. https://doi.org/10.3389/fimmu.2025.1569864Zhang Z., Lin Y., Chen S. Efficacy of neoadjuvant, adjuvant, and perioperative immunotherapy in non-small cell lung cancer across different PD-L1 expression levels: a systematic review and meta-analysis. Front Immunol 2025;16:1569864. https://doi.org/10.3389/fimmu.2025.1569864Meng Y., Han H., Zhu S., et al. Identifying patients who benefit more from perioperative immunotherapy combinations for resectable non-small cell lung cancer based on clinical and molecular characteristics: a meta-analysis of randomized clinical trials. Clin Transl Oncol 2025;27(4):1516–1528. https://doi.org/10.1007/s12094-024-03712-0Meng Y., Han H., Zhu S., et al. Identifying patients who benefit more from perioperative immunotherapy combinations for resectable non-small cell lung cancer based on clinical and molecular characteristics: a meta-analysis of randomized clinical trials. Clin Transl Oncol 2025;27(4):1516–1528. https://doi.org/10.1007/s12094-024-03712-0Calles A., Riess J.W., Brahmer J.R. Checkpoint blockade in lung cancer with driver mutation: choose the road wisely. Am Soc Clin Oncol Educ Book 2020;40:372–384. https://doi.org/10.1200/EDBK_280795Calles A., Riess J.W., Brahmer J.R. Checkpoint blockade in lung cancer with driver mutation: choose the road wisely. Am Soc Clin Oncol Educ Book 2020;40:372–384. https://doi.org/10.1200/EDBK_280795Bylicki O., Paleiron N., Margery J., et al. Targeting the PD-1/PD-L1 immune checkpoint in EGFR-mutated or ALK-translocated non-small-cell lung cancer. Target Oncol 2017;12(5):563–569. https://doi.org/10.1007/s11523-017-0510-9Bylicki O., Paleiron N., Margery J., et al. Targeting the PD-1/PD-L1 immune checkpoint in EGFR-mutated or ALK-translocated non-small-cell lung cancer. Target Oncol 2017;12(5):563–569. https://doi.org/10.1007/s11523-017-0510-9Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026Chen D.S., Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature 2017;541(7637):321–330. https://doi.org/10.1038/nature21349 19. Chiou V.L., Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 2015;33(31):3541–3. https://doi.org/10.1200/JCO.2015.61.6870Chen D.S., Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature 2017;541(7637):321–330. https://doi.org/10.1038/nature21349 19. Chiou V.L., Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 2015;33(31):3541–3. https://doi.org/10.1200/JCO.2015.61.6870Ferrara R., Mezquita L., Texier M., et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol 2018;4(11):1543–1552. https://doi.org/10.1001/jamaoncol.2018.3676Ferrara R., Mezquita L., Texier M., et al. Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol 2018;4(11):1543–1552. https://doi.org/10.1001/jamaoncol.2018.3676Nelles C., Gräf M., Bernard P., et al. Real-world response assessment of immune checkpoint inhibition: comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients. Eur Radiol 2025;35(4):2084–2093. https://doi.org/10.1007/s00330-024-11060-4Nelles C., Gräf M., Bernard P., et al. Real-world response assessment of immune checkpoint inhibition: comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients. Eur Radiol 2025;35(4):2084–2093. https://doi.org/10.1007/s00330-024-11060-4Lopci E., Toschi L., Grizzi F., et al. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. Eur J Nucl Med Mol Imaging 2016;43(11):1954–61. https://doi.org/10.1007/s00259-016-3425-2Lopci E., Toschi L., Grizzi F., et al. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. Eur J Nucl Med Mol Imaging 2016;43(11):1954–61. https://doi.org/10.1007/s00259-016-3425-2Chen Z.Y., Fu R., Tan X.Y., et al. Dynamic 18 F-FDG PET/CT can predict the major pathological response to neoadjuvant immunotherapy in non-small cell lung cancer. Thorac Cancer 2022;13(17):2524–2531. https://doi.org/10.1111/1759-7714.14562Chen Z.Y., Fu R., Tan X.Y., et al. Dynamic 18 F-FDG PET/CT can predict the major pathological response to neoadjuvant immunotherapy in non-small cell lung cancer. Thorac Cancer 2022;13(17):2524–2531. https://doi.org/10.1111/1759-7714.14562Zhang C., Liu J., Tong J., et al. 18F-FDG-PET evaluation of pathological tumour response to neoadjuvant therapy in patients with NSCLC. Nucl Med Commun 2013;34(1):71–7. https://doi.org/10.1097/MNM.0b013e3283599999Zhang C., Liu J., Tong J., et al. 18F-FDG-PET evaluation of pathological tumour response to neoadjuvant therapy in patients with NSCLC. Nucl Med Commun 2013;34(1):71–7. https://doi.org/10.1097/MNM.0b013e3283599999Castello A., Rossi S., Lopci E. 18F-FDG PET/CT in restaging and evaluation of response to therapy in lung cancer: state of the art. Curr Radiopharm 2020;13(3):228–237. https://doi.org/10.2174/1874471013666191230144821Castello A., Rossi S., Lopci E. 18F-FDG PET/CT in restaging and evaluation of response to therapy in lung cancer: state of the art. Curr Radiopharm 2020;13(3):228–237. https://doi.org/10.2174/1874471013666191230144821Orr L., Krochmal R., Sonti R., et al. Comparison of the GenCut core biopsy system to transbronchial biopsy forceps for flexible bronchoscopic lung biopsy. J Bronchology Interv Pulmonol 2022;29(2):140–145. https://doi.org/10.1097/LBR.0000000000000803Orr L., Krochmal R., Sonti R., et al. Comparison of the GenCut core biopsy system to transbronchial biopsy forceps for flexible bronchoscopic lung biopsy. J Bronchology Interv Pulmonol 2022;29(2):140–145. https://doi.org/10.1097/LBR.0000000000000803Sethi J., Ali M.S., Mohananey D., et al. Are transbronchial cryobiopsies ready for prime time?: a systematic review and meta-analysis. J Bronchology Interv Pulmonol 2019;26(1):22–32. https://doi.org/10.1097/LBR.0000000000000519Sethi J., Ali M.S., Mohananey D., et al. Are transbronchial cryobiopsies ready for prime time?: a systematic review and meta-analysis. J Bronchology Interv Pulmonol 2019;26(1):22–32. https://doi.org/10.1097/LBR.0000000000000519Sano M., Oki M. Transthoracic lung biopsy: diagnostic accuracy and complications. Transl Cancer Res 2023;12(2):233– 235. https://doi.org/10.21037/tcr-22-2703Sano M., Oki M. Transthoracic lung biopsy: diagnostic accuracy and complications. Transl Cancer Res 2023;12(2):233– 235. https://doi.org/10.21037/tcr-22-2703Sasani M.R., Paknahad M. Complications of CT-guided percutaneous lung biopsy: a 1-year single-center experience in Iran. Med J Islam Repub Iran 2025;39:102. https://doi.org/10.47176/mjiri.39.102Sasani M.R., Paknahad M. Complications of CT-guided percutaneous lung biopsy: a 1-year single-center experience in Iran. Med J Islam Repub Iran 2025;39:102. https://doi.org/10.47176/mjiri.39.102Bartolomucci A., Nobrega M., Ferrier T., et al. Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology. NPJ Precis Oncol 2025;9(1):84. https://doi.org/10.1038/s41698-025-00876-yBartolomucci A., Nobrega M., Ferrier T., et al. Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology. NPJ Precis Oncol 2025;9(1):84. https://doi.org/10.1038/s41698-025-00876-yPellini B., Chaudhuri A.A. Circulating tumor DNA minimal residual disease detection of non-small-cell lung cancer treated with curative intent. J Clin Oncol 2022;40(6):567–575. https://doi.org/10.1200/JCO.21.01929Pellini B., Chaudhuri A.A. Circulating tumor DNA minimal residual disease detection of non-small-cell lung cancer treated with curative intent. J Clin Oncol 2022;40(6):567–575. https://doi.org/10.1200/JCO.21.01929Cascone T., Awad M.M., Spicer J.D., et al. CheckMate 77T investigators. Perioperative nivolumab in resectable lung cancer. N Engl J Med 2024;390(19):1756–1769. https://doi.org/10.1056/NEJMoa2311926Cascone T., Awad M.M., Spicer J.D., et al. CheckMate 77T investigators. Perioperative nivolumab in resectable lung cancer. N Engl J Med 2024;390(19):1756–1769. https://doi.org/10.1056/NEJMoa2311926Forde P.M., Spicer J., Lu S. Provencio, M., et al. CheckMate 816 Investigators. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 2022;386(21):1973–1985. https://doi.org/10.1056/NEJMoa2202170Forde P.M., Spicer J., Lu S. Provencio, M., et al. CheckMate 816 Investigators. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 2022;386(21):1973–1985. https://doi.org/10.1056/NEJMoa2202170Chen K., Zhao H., Shi Y., et al. Perioperative dynamic changes in circulating tumor DNA in patients with lung cancer (DYNAMIC). Clin Cancer Res 2019;25(23):7058–7067. https://doi.org/10.1158/1078-0432.CCR-19-1213Chen K., Zhao H., Shi Y., et al. Perioperative dynamic changes in circulating tumor DNA in patients with lung cancer (DYNAMIC). Clin Cancer Res 2019;25(23):7058–7067. https://doi.org/10.1158/1078-0432.CCR-19-1213Abbosh C., Frankell A., Garnett A., et al. Phylogenetic tracking and minimal residual disease detection using ctDNA in early-stage NSCLC: A lung TRACERx study. AACR Annual Meeting 2020;80 (16_Supplement):CT023-CT023. https://doi.org/10.1158/1538-7445.AM2020-CT023Abbosh C., Frankell A., Garnett A., et al. Phylogenetic tracking and minimal residual disease detection using ctDNA in early-stage NSCLC: A lung TRACERx study. AACR Annual Meeting 2020;80 (16_Supplement):CT023-CT023. https://doi.org/10.1158/1538-7445.AM2020-CT023Reck M., Gale D., Harpole D, et al. LBA59 Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial. Ann Oncol 2023;34:S1300. https://doi.org/10.1016/j.annonc.2023.10.055Reck M., Gale D., Harpole D, et al. LBA59 Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial. Ann Oncol 2023;34:S1300. https://doi.org/10.1016/j.annonc.2023.10.055Liu T., Zhang W., Liu C., et al. Efficacy of endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of mediastinal and hilar lesions. Curr Med Imaging 2024;20. https://doi.org/10.2174/1573405620666230428121243Liu T., Zhang W., Liu C., et al. Efficacy of endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of mediastinal and hilar lesions. Curr Med Imaging 2024;20. https://doi.org/10.2174/1573405620666230428121243Chrysikos S., Karampitsakos T., Zervas E., et al. Thoracic endosonography (EBUS/EUS-b) in the diagnosis of different intrathoracic diseases: A 4-year experience at a single-centre in Greece. Int J Clin Pract 2021;75(3):e13684. https://doi.org/10.1111/ijcp.13684Chrysikos S., Karampitsakos T., Zervas E., et al. Thoracic endosonography (EBUS/EUS-b) in the diagnosis of different intrathoracic diseases: A 4-year experience at a single-centre in Greece. Int J Clin Pract 2021;75(3):e13684. https://doi.org/10.1111/ijcp.13684Hong G., Oki M. Transesophageal endoscopic ultrasound with bronchoscope-guided fine-needle aspiration for diagnostic and staging purposes: a narrative review. J Thorac Dis 2023;15(9):5088–5098. https://doi.org/10.21037/jtd-23-681Hong G., Oki M. Transesophageal endoscopic ultrasound with bronchoscope-guided fine-needle aspiration for diagnostic and staging purposes: a narrative review. J Thorac Dis 2023;15(9):5088–5098. https://doi.org/10.21037/jtd-23-681Vilmann P., Clementsen P.F., Colella S., et al. Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). Endoscopy 2015;47(6):545–59. https://doi.org/10.1055/s-0034–1392040. Erratum in: Endoscopy 2015;47(6):c1. https://doi.org/10.1055/s-0034-1392453Vilmann P., Clementsen P.F., Colella S., et al. Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). Endoscopy 2015;47(6):545–59. https://doi.org/10.1055/s-0034–1392040. Erratum in: Endoscopy 2015;47(6):c1. https://doi.org/10.1055/s-0034-1392453Erasmus L.T., Strange T.A., Agrawal R., et al. Lung cancer staging: imaging and potential pitfalls. Diagnostics (Basel) 2023;13(21):3359. https://doi.org/10.3390/diagnostics13213359Erasmus L.T., Strange T.A., Agrawal R., et al. Lung cancer staging: imaging and potential pitfalls. Diagnostics (Basel) 2023;13(21):3359. https://doi.org/10.3390/diagnostics13213359Kremer R., Peysakhovich Y., Dan L.F., et al. FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy. Ann Nucl Med 2016;30(2):114–21. https://doi.org/10.1007/s12149-015-1038-7Kremer R., Peysakhovich Y., Dan L.F., et al. FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy. Ann Nucl Med 2016;30(2):114–21. https://doi.org/10.1007/s12149-015-1038-7Liu X., Duan B., Liu R., et al. Enhancing clinical complete response assessment in rectal cancer: integrating transanal multipoint full-layer puncture biopsy criteria: a systematic review. Front Oncol 2024;14:1428583. https://doi.org/10.3389/fonc.2024.1428583Liu X., Duan B., Liu R., et al. Enhancing clinical complete response assessment in rectal cancer: integrating transanal multipoint full-layer puncture biopsy criteria: a systematic review. Front Oncol 2024;14:1428583. https://doi.org/10.3389/fonc.2024.1428583Gu C., Teng X., Sun X., et al. Impact of treatment interval between neoadjuvant immunochemotherapy and surgery in lung squamous cell carcinoma. BMC Cancer 2024;24(1):585. https://doi.org/10.1186/s12885-024-12333-3Gu C., Teng X., Sun X., et al. Impact of treatment interval between neoadjuvant immunochemotherapy and surgery in lung squamous cell carcinoma. BMC Cancer 2024;24(1):585. https://doi.org/10.1186/s12885-024-12333-3Chen J., Deng H., He J., et al. Impact of the interval between neoadjuvant immunochemotherapy and surgery on surgical-pathological outcomes in non-small cell lung cancer. Front Oncol 2022;12:909726. https://doi.org/10.3389/fonc.2022.909726Chen J., Deng H., He J., et al. Impact of the interval between neoadjuvant immunochemotherapy and surgery on surgical-pathological outcomes in non-small cell lung cancer. Front Oncol 2022;12:909726. https://doi.org/10.3389/fonc.2022.909726Lococo F., Sassorossi C., Nachira D., et al. Prognostic factors and long-term survival in locally advanced NSCLC with pathological complete response after surgical resection following neoadjuvant therapy. Cancers (Basel) 2020;12(12):3572. https://doi.org/10.3390/cancers12123572Lococo F., Sassorossi C., Nachira D., et al. Prognostic factors and long-term survival in locally advanced NSCLC with pathological complete response after surgical resection following neoadjuvant therapy. Cancers (Basel) 2020;12(12):3572. https://doi.org/10.3390/cancers12123572İşgörücü Ö., Citak N. Survival analysis of pathological complete response of locally advanced lung cancer after neoadjuvant treatment. Gen Thorac Cardiovasc Surg 2021;69(7):1086–1095. https://doi.org/10.1007/s11748-020-01584-zİşgörücü Ö., Citak N. Survival analysis of pathological complete response of locally advanced lung cancer after neoadjuvant treatment. Gen Thorac Cardiovasc Surg 2021;69(7):1086–1095. https://doi.org/10.1007/s11748-020-01584-zMcMurry T.L., Stukenborg G.J., Kessler L.G., et al. More frequent surveillance following lung cancer resection is not associated with improved survival: a nationally representative cohort study. Ann Surg 2018;268(4):632–639. https://doi.org/10.1097/SLA.0000000000002955McMurry T.L., Stukenborg G.J., Kessler L.G., et al. More frequent surveillance following lung cancer resection is not associated with improved survival: a nationally representative cohort study. Ann Surg 2018;268(4):632–639. https://doi.org/10.1097/SLA.0000000000002955Bodor J.N., Feliciano J.L., Edelman M.J. Outcomes of patients with disease recurrence after treatment for locally advanced non-small cell lung cancer detected by routine follow-up CT scans versus a symptom driven evaluation. Lung Cancer 2019;135:16–20. https://doi.org/10.1016/j.lungcan.2019.07.009. Erratum in: Lung Cancer 2019;136:157. https://doi.org/10.1016/j.lungcan.2019.08.015Bodor J.N., Feliciano J.L., Edelman M.J. Outcomes of patients with disease recurrence after treatment for locally advanced non-small cell lung cancer detected by routine follow-up CT scans versus a symptom driven evaluation. Lung Cancer 2019;135:16–20. https://doi.org/10.1016/j.lungcan.2019.07.009. Erratum in: Lung Cancer 2019;136:157. https://doi.org/10.1016/j.lungcan.2019.08.015Schneider B.J., Ismaila N., Aerts J., et al. Lung cancer surveillance after definitive curative-intent therapy: ASCO guideline. J Clin Oncol 2020;38(7):753–766. https://doi.org/10.1200/JCO.19.02748Schneider B.J., Ismaila N., Aerts J., et al. Lung cancer surveillance after definitive curative-intent therapy: ASCO guideline. J Clin Oncol 2020;38(7):753–766. https://doi.org/10.1200/JCO.19.02748Федянин М.Ю., Гладков О.А., Гордеев С.С. и соавт. Рак ободочной кишки, ректосигмоидного соединения и прямой кишки. Клинические рекомендации RUSSCO, часть 1.1. Злокачественные опухоли 2025;15(3s2):310–372. https://doi.org/10.18027/2224-5057-2025-15-3s2-1.1-14.Fedyanin M.Yu., Gladkov O.A., Gordeev S.S., et al. Сancer of the colon, rectosigmoid junction and rectum. Klinicheskiye rekomendatsii RUSSСO, chast’ 1.1. Zlokachestvennyye opukholi = Clinical guidelines RUSSCO, part 1.1. Malignant tumors 2025;15(3s2):310–372 (In Russ.). https://doi.org/10.18027/2224-5057-2025-15-3s2-1.1-14Bar J., Maiocco G.D., Parikh K., et al. Real world characteristics of stages II-III NSCLC patients (pts) who initiate neoadjuvant chemo-immunotherapy (NACT-I) and do not undergo surgical resection. Clin Oncol 2025;43(8019):16_suppl. https://doi.org/10.1200/JCO.2025.43.16_suppl.8019Bar J., Maiocco G.D., Parikh K., et al. Real world characteristics of stages II-III NSCLC patients (pts) who initiate neoadjuvant chemo-immunotherapy (NACT-I) and do not undergo surgical resection. Clin Oncol 2025;43(8019):16_suppl. https://doi.org/10.1200/JCO.2025.43.16_suppl.8019Lococo F., Sassorossi C., Nachira D., et al. Prognostic factors and long-term survival in locally advanced NSCLC with pathological complete response after surgical resection following neoadjuvant therapy. Cancers (Basel) 2020;12(12):3572. https://doi.org/10.3390/cancers12123572Lococo F., Sassorossi C., Nachira D., et al. Prognostic factors and long-term survival in locally advanced NSCLC with pathological complete response after surgical resection following neoadjuvant therapy. Cancers (Basel) 2020;12(12):3572. https://doi.org/10.3390/cancers12123572Kayawake H., Okumura N., Yamanashi K., et al. Non-small cell lung cancer with pathological complete response: predictive factors and surgical outcomes. Gen Thorac Cardiovasc Surg 2019;67(9):773–781. https://doi.org/10.1007/s11748-019-01076-9Kayawake H., Okumura N., Yamanashi K., et al. Non-small cell lung cancer with pathological complete response: predictive factors and surgical outcomes. Gen Thorac Cardiovasc Surg 2019;67(9):773–781. https://doi.org/10.1007/s11748-019-01076-9Chicas-Sett R., Zafra .J, Rodriguez-Abreu D., et al. Combination of SABR with Anti-PD-1 in oligoprogressive nonsmall cell lung cancer and melanoma: results of a prospective multicenter observational study. Int J Radiat Oncol Biol Phys 2022;114(4):655–665. https://doi.org/10.1016/j.ijrobp.2022.05.013Chicas-Sett R., Zafra .J, Rodriguez-Abreu D., et al. Combination of SABR with Anti-PD-1 in oligoprogressive nonsmall cell lung cancer and melanoma: results of a prospective multicenter observational study. Int J Radiat Oncol Biol Phys 2022;114(4):655–665. https://doi.org/10.1016/j.ijrobp.2022.05.013Schreiner W., Dudek W., Lettmaier S., et al. Should salvage surgery be considered for local recurrence after definitive chemoradiation in locally advanced non-small cell lung cancer? J Cardiothorac Surg 2016;11:9. https://doi.org/10.1186/s13019-016-0396-0.Schreiner W., Dudek W., Lettmaier S., et al. Should salvage surgery be considered for local recurrence after definitive chemoradiation in locally advanced non-small cell lung cancer? J Cardiothorac Surg 2016;11:9. https://doi.org/10.1186/s13019-016-0396-0.

The authors declare that there are no conflicts of interest present.